August 2012
-
A randomized, double-blind, Phase 2b dose-ranging study of Pearl Therapeutics’ formoterol fumarate MDI compared to Foradil Aerolizer and placebo showed statistically significant benefits in patients with moderate-to-severe COPD, according to the company. The metered dose… Read more . . .
-
Contract research company Gateway Analytical has received certification under ISO standard 9001:2008 for its analytical laboratory process quality management system. The laboratory, which provides ingredient-specific particle sizing for nasal sprays and inhalers among other services,… Read more . . .
-
The United States Court of Appeals has upheld a patent for Fortical calcitonin nasal spray held by Unigene Laboratories. Fortical, a bioequivalent of Novartis’s Miacalcin, is marketed in the US by Unigene subsidiary Upsher-Smith for… Read more . . .
-
A randomized, double-blind study conducted by researchers from the University of Cincinnati has shown that a capsaicin nasal spray available over the counter significantly relieved nasal congestion, sinus pain, sinus pressure, and headache in patients… Read more . . .
-
British biopharmaceutical company Lightlake Therapeutics has announced that it will begin Phase 2 trials of its naloxone nasal spray for the treatment of binge eating disorder in overweight and obese patients on August 26th, 2011… Read more . . .
-
A study by University of Washington researchers published in the September 2011 issue of Anesthesia & Analgesia, the official journal of the International Anesthesia Research Society, demonstrates improved delivery of morphine and fentanyl in rats… Read more . . .
-
Physical Properties Scientist, GlaxoSmithKline, Ware, Hertfordshire Basic qualifications: Extensive experience in pharmaceutical development, and physical property characterisation. A good knowledge of analytical techniques relating to solid state and powder properties and the ability to work… Read more . . .
-
Verona Pharma has successfully completed a Phase 2 study of the duration of bronchodilator action by its lead drug RPL554 in patients with mild asthma, according to the company. RPL554 is a novel long-acting phosphodiesterase… Read more . . .
-
After the FDA’s acceptance of Alexza Pharmaceuticals’s resubmitted NDA for Adasuve, the company has announced that the Prescription Drug User Fee Act (PDUFA) goal date will be February 4, 2012. Alexza had received a complete… Read more . . .
-
The FDA has approved a pre-market approval (PMA) application from Intersect ENT for its Propel mometasone furoate drug delivery implant for the treatment of chronic sinusitis. The dissolvable device is inserted in the sinus cavity… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland